C A Uyl-de Groot
Overview
Explore the profile of C A Uyl-de Groot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xander N, Leeneman B, Dingemans A, Fiets W, de Jong W, Uyl N, et al.
Eur J Cancer
. 2024 Aug;
209:114262.
PMID: 39111205
Background: The Dutch Committee for the Evaluation of Oncological Agents (cieBOM) assesses the clinical benefit of systemic anti-cancer treatments (SACTs). For SACTs tested in non-randomized trials (NRTs), cieBOM primarily utilizes...
2.
Heine R, Thielen F, Mathijssen R, van Leeuwen R, Franken M, Uyl-de Groot C
PLoS One
. 2024 Feb;
19(2):e0293264.
PMID: 38300937
Background: Expanding the indication of already approved immuno-oncology drugs presents treatment opportunities for patients but also strains healthcare systems. Cost-based pricing models are discussed as a possibility for cost containment....
3.
Franken M, Leeneman B, Aarts M, van Akkooi A, van den Berkmortel F, Boers-Sonderen M, et al.
ESMO Open
. 2021 Dec;
6(6):100320.
PMID: 34856511
Background: The objective of this study was to evaluate trends in survival and health care costs in metastatic melanoma in the era of targeted and immunotherapeutic drugs. Materials And Methods:...
4.
Mulder E, Smit L, Grunhagen D, Verhoef C, Sleijfer S, van der Veldt A, et al.
ESMO Open
. 2021 Nov;
6(6):100303.
PMID: 34781194
Background: The introduction of adjuvant systemic treatment has significantly improved recurrence-free survival in patients with resectable high-risk melanoma. Adjuvant treatment with immune checkpoint inhibitors and targeted therapy, however, substantially impacts...
5.
Visser L, Huls S, Uyl-de Groot C, de Bekker-Grob E, Redekop W
J Neurol Sci
. 2021 Aug;
428:117587.
PMID: 34364148
Background: Persons with multiple sclerosis (MS) take their treatment via pills, injections or infusions. A novel mode of disease-modifying treatment administration, an implantable device, is under development. This study determined...
6.
Westgeest H, Kuppen M, van den Eertwegh A, de Wit R, Bergman A, van Moorselaar R, et al.
Prostate Cancer Prostatic Dis
. 2021 Mar;
24(3):871-879.
PMID: 33746212
Background: In 2004 docetaxel was the first life-prolonging drug (LPD) registered for metastatic castration-resistant prostate cancer (mCRPC) patients. Between 2011 and 2014 new LPDs for mCRPC (cabazitaxel, abiraterone, enzalutamide, and...
7.
Van der Linden N, Van Olst S, Nekeman S, Uyl-de Groot C
Diabet Med
. 2020 Aug;
38(4):e14371.
PMID: 32745279
Aim: When glycaemic control for people with type 2 diabetes is not achieved with metformin and sulfonylurea alone, adding another oral anti-diabetes drug, such as a sodium-glucose co-transporter 2 (SGLT2)...
8.
Visser L, Louapre C, Uyl-de Groot C, Redekop W
Mult Scler Relat Disord
. 2020 Jan;
39:101929.
PMID: 31924590
Background: Considering the multiple treatments approved for multiple sclerosis (MS) by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), determining a treatment strategy for patients with clinically...
9.
van Ommen-Nijhof A, Konings I, van Zeijl C, Uyl-de Groot C, van der Noort V, Jager A, et al.
BMC Cancer
. 2018 Nov;
18(1):1146.
PMID: 30458732
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is an effective strategy to improve progression-free survival in hormone receptor-positive (HR+), human epidermal growth factor receptor 2...
10.
Oosten L, Chamuleau M, Thielen F, de Wreede L, Siemes C, Doorduijn J, et al.
Ann Hematol
. 2017 Dec;
97(2):255-266.
PMID: 29209924
Burkitt lymphoma is an aggressive B cell malignancy accounting for 1-2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy is effective but associated with considerable toxicity. In this observational...